RxDoctor Payments Data

Lisa Allen, MD

Rheumatology · Lancaster, PANPI 1710961230

Payments from drug & device makers

$789in general payments, 2019–2025

Across 17 payments — averaging $46.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Elucent Medical$500
  • Johnson & Johnson$85
  • GSK$52
  • Novartis$47
  • AstraZeneca$34
  • Amgen$29
  • plus $43 from 3 others

What the payments were for

  • Speaking & faculty fees$50063%
  • Food & beverage$28937%

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Elucent Medical1$500
Johnson & Johnson(2 entities)4$85
GSK3$52
Novartis3$47
AstraZeneca1$34
Amgen2$29
Bristol Myers Squibb1$18
Pfizer1$13
Lilly USA, LLC1$11

How this compares

$789 in reported general payments places this provider in the 35th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$734,591
Medicare patients
1,381
Services billed
70,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$382,966
Enbrel SureclickEtanercept18$187,658
XeljanzTofacitinib Citrate15$83,951
OtezlaApremilast22$74,245
Actemra ActpenTocilizumab15$38,846
Teriparatide15$34,785
Hydroxychloroquine Sulfate650$25,446
RasuvoMethotrexate/Pf17$14,558
MethotrexateMethotrexate Sodium202$6,116
Mycophenolate Mofetil41$3,810
Duloxetine Hcl162$3,462
Gabapentin200$2,416
Sulfasalazine67$2,351
Risedronate Sodium26$2,115
Leflunomide45$1,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$13$83,95115 claims
AmgenOtezla$29$74,24522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →